Papers

1. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC.  Predictors of survival in a cohort of patients with polymyositis and dermatomyositis:  effect of corticosteroids, methotrexate, and azathioprine.  Arthritis Research & Therapy 2012, 14:R22. doi:10.1186/ar3704
   
   

2. PDE-5 Inhibitors in Scleroderma related Raynaud Phenomenon and digital ulcers: current status of clinical trials. International Journal of Rheumatology. Volume 2011 (2011), Article ID 392542, 5 pages. doi:10.1155/2011/392542
   
   
3. Impens AJ, Phillips K, Schiopu E. PDE-5 Inhibitors in Scleroderma related Raynaud Phenomenon and digital ulcers: current status of clinical trials. International Journal of Rheumatology. Volume 2011 (2011), Article ID 392542, 5 pages. doi:10.1155/2011/392542
   
   
4. Hinchcliff M, Fischer A, Schiopu E, Steen V for the PHAROS investigators.  Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population. The Journal of Rheumatology, 2011 Aug 15. [Epub ahead of print]
   
   
5. Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention.  Clin Exp Rheumatol. 2011 Mar-Apr;29 (2 Suppl 65):S22-5. Epub 2011 May 12. PubMed PMID: 21586214.
   
   
6. Baron M, Hudson M, Steele R, Lo E. Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis. J Rheumatol. 2011 Jul 1. [Epub ahead of print] PubMed PMID: 21724704.
   
   
7. Bae S, Allanore Y, Coustet B, Maranian P, Khanna D. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  Clin Exp Rheumatol. 2011 Mar-Apr;29 (2 Suppl 65):S15-21. Epub 2011 May 12. PubMed PMID: 21586213.
   
   
8. Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Hays RD. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  J Rheumatol. 2011Jul 1. [Epub ahead of print] PubMed PMID: 21724699.
   
   
9. Frech T, Hays RD, Maranian P, Clements PJ, Furst DE, Khanna D. Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.  Rheumatology (Oxford). 2011 Jul;50(7):1280-7. Epub 2011 Feb 15. PubMed PMID: 21324979; PubMed Central PMCID: PMC3116211.
   
   
10. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.  Rheumatology (Oxford). 2011 Feb;50(2):330-4. Epub 2010 Sep 30. PubMed PMID: 20884655; PubMed Central PMCID: PMC3021949.
    
    
11. Is it Time to Replace the HAQ?  The PROMIS initiative uses item response theory to improve assessment of patient-reported health and wellbeing– an article featuring Dinesh Khanna, MD, MS and colleagues in The Rheumatologist, July 2011 issue.
    
    
12. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D: Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis ;Rheumatology, doi: 10.1093/rheumatology/keq296, 2010.
    
    
13. Impens AJ, Seibold JR: Vascular alterations and sexual function in systemic sclerosis International Journal of Rheumatology, Article ID 139020, doi: 10.1155/2010/139020, 2010.
    
    
14. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE:  Reliability and Validity of the University ofCalifornia, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  Arthritis & Rheumatism (Arthritis Care & Research) 61(9):1257-1263, 2009.
    
    
15. Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR. Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud Phenomenon Secondary to Systemic Sclerosis. J Rheumatol 36(10):2264-8, 2009.
    
    
16. Impens A, Rothman J, Schiopu E, Cole J, Dang J, Gendrano N, Rosen R, Seibold JR. Sexual Activity and Functioning in Female Scleroderma Patients. Clin Exp Rheumatol 27 (Suppl 54 Scleroderma Care and Research); S38-43, 2009.
    
    
17. Seibold JR, Benza R, Davie N, Frost A, Gaine S, Hill NS, Highland K, Langleben D, Naeije R: One-year open label comparison of sitaxentan to bosentan in treatment of pulmonary arterial hypertension related to systemic sclerosis. Ann Rheum Dis 2009; 68(3): 463.
    
    
18. Seibold JR, Benza R, Davie N, Frost A, Gaine S, Hill NS, Highland K, Langleben D, Naeije R: Long term results of sitaxentan therapy in pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2009; 68(3): 462.
    
    
19. Phillips K, Byrne-Dugan C, Batterson E, Seibold JR: Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis (PDF). Nature Reviews Rheumatology 5:225-228, 2009.
    
    
20. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. (PDF) Ann Rheum Dis 66:1641-1647, 2007.
    
    
21. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin D, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes M, McDonagh KT, McLaughlin B, Molitor J, Nelson JL, Shulman H, Storb R, Viganego F, Wener M, Seibold JR, Sullivan KM, Furst DE. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: U.S. multicenter pilot study. (PDF) Blood DOI 10.1182/blood-2007-02-072389.
    
    
22. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver R, Goldin J, Arriola E, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M. Effects of a one-year treatment with cyclophosphamide on outcomes at two years in scleroderma lung disease. (PDF) Am J Resp Crit Care Med doi: 10.1164/rccm.2007 02-3260C.
    
    
23. Tashkin DP, Bashoff R, Clements PJ, Goldin J, Rith MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M: Cyclophosphamide versus placebo in Scleroderma Lung Disease. (PDF) N Engl J Med 354:2655-2666, 2006
    
    
24. Seibold JR, Langleben D, Badesch D, Naeije R, Galie N, Barst RJ: Sitaxsentan, a selective endothelin-A receptor antagonist, improves exercise capacity in PAH associated with CTD (PDF) Ann Rheum Dis 65(11):S522, 2006.
    
    
25. Black, C, Denton CP, Furst DE, Matucc-Cerinic M, Mayes MD, Pope JE, Seibold JR, Morganti A, Kramer F, Korn JH: Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis: Open-label extension to a double-blind trial (PDF) Ann Rheum Dis 65(11):S384-85, 2006.
    
    
26. Seibold JR, Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Kramer F, Morganti A, Korn JH: Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. (PDF) Ann Rheum Dis 65(11):S90, 2006.
    
    
27. Seibold JR, Black CM, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Charef P, Roux S, Chadha-Boreham H: Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis:  The Build 2 study.  (PDF)  Proc Am Thorac Soc 3:A243; 2006.
    
    
28. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ: Bosentan in Pulmonary Arterial Hypertension Secondary to Scleroderma. (PDF) J Rheumatol 33:61-8, 2006.
    
    
29. Seibold JR, Denton CP, Furst DE, Matucci-Cerinic M, Mayes MD, Morganti A, Kramer F, Korn JH: Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc). (PDF) (Late breaking abstract, ACR National Meeting, November, 2005).

Posters

1. Wangkaew S, Impens AJ, Rubenfire M, Schiopu E, McLaughlin VV, Montgomery DG, Seibold JR:  Correlation between submaximal exercise testing and right heart catheterization in patients with systemic sclerosis (SSc) (PDF) Abstract, ACR National Meeting, 2009.

2. Impens AJ, Hinchcliff ME, Hummers LK, Mayes MM, Derk CT, Shapiro LS, Domsic RT, Segal BM, Goldberg AZ, Alkassab F, Steen VD, and the PHAROS Investigators:  Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS):  Utility of six minute walk test (PDF) Abstract, ACR National Meeting, 2009.

3. Mahmood F, Impens AJ, Schiopu E, Phillips K, Lowe L, Olsen S, Seibold JR: Clinical and histopathologic comparison of generalized subcutaneous morphea (GSM) with eosinophilic fasciitis (EF) (PDF) Abstract, ACR National Meeting, 2009.
   

4. Seibold JR, Denton CP, Distler O, Grnig E, McLaughlin V, Müller-Ladner U, Pope J, Vonk M, Coghlan G:  The DETECT study:  A two-stage, prospective, observational, cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. (PDF) Abstract, ACR National Meeting, 2008.
   

5. Chan KM, Tishkowski E, Impens AJ, Ojo T, McLaughlin VV, Seibold JR.  Doppler echocardiography overestimates pulmonary hypertension in patients with scleroderma interstitial lung disease. (PPT) Abstract, ACR National Meeting, 2008.
   

6. Impens AJ, Wangkaew S, Rubenfire M, McLaughlin VV, Montgomery DG, Seibold JR.  Correlations of 6-minute walk distance (6MWD) with subjective measures of dyspnea in systemic sclerosis (SSc) patients. (PDF) Abstract, ACR National Meeting, 2008.
   

7. Hou Y, Rabquer BJ, Jaffe ML, Del Galdo F, Jimenez SA, Haines III GK, Seibold JR, Barr WG, Massa MC, Koch AE. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. (PDF) Abstract, ACR National Meeting, 2008.
   

8. Rabquer BJ, Hou Y, Del Galdo F, Haines III GK, Jaffe ML, Jimenez SA, Seibold JR, Koch AE. The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion. (PDF) Abstract, ACR National Meeting, 2008.
   

9. Schiopu E, Impens AJ, Phillips K, Denton CP, Furst DE, Guillevin L, Rugin LJ, Wells AU, Matucci-Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S Black CM, Seibold JR:  Sub-maximal exercise testing in the prospective assessment of interstitial lung disease (ILD) secondary to systemic sclerosis (SSc):  Correlations with objective and subjective measures of parenchymal lung disease. (PDF) Abstract, ACR National Meeting, 2007.
   
   
10. Schiopu E, Hsu VM, Hummers L, Shapiro L, Mayes MD, Csuka ME, Derk C, Chung L, Varga J, Furst DE, Silver RM, Wigley FM, Seibold JR, Steen VD:  Pulmonary hypertension assessment and reaction of outcomes in scleroderma (systemic sclerosis, SSc):  PHAROS. (PDF) Abstract, ACR National Meeting, 2007.
    
    
11. Impens AJ, Schiopu E, Phillips K, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, Matucci-Cerinic M, Riemekasten G, Emory P, Chada-Boreham H, Charef P, Roux S, Black CM, Seibold JR:  Correlations of objective ratings of respiratory function with traditional measures of parenchymal lung disease in systemic sclerosis (SSc) patients with interstitial lung disease. (PDF) Abstract, ACR National Meeting, 2007.
    
    
12. Impens AJ, Schiopu E, Buch MH, Seibold JR:  Physician and patient assessment of disease severity in systemic sclerosis (SSc). (PDF) Abstract, ACR National Meeting, 2007.
    
    
13. Impens AJ, Guerriere J, Schiopu E, Gendrano N, Seibold JR, Rosen RC:  Sexual activity and functioning in female scleroderma (SSc) patients. (PDF) Abstract, American Psychological Association National Meeting, 2007.
    
    
14. Impens AJ, Chung KC, Buch MH, Schiopu E, Kotsis S, Burns P, Seibod JR:  Comparison of pain scales in systemic sclerosis (SSc) patients. (PDF) Abstract, EULAR, 2007.
    
    
15. Impens AJ, Chung KC, Buch MH, Schiopu E, Kotsis S, Burns P, Seibold JR: Influences of clinical features of systemic sclerosis (SSc) on the Michigan Hand Questionnaire (MHQ). (PDF) Abstract, ACR National Meeting, 2006.
    
    
16. Impens AJ, Chung KC, Buch MH, Schiopu E, Kotsis S, Burns P, Seibold JR: Validation of the Michigan Hand Outcomes Questionnaire (MHQ) in Systemic Sclerosis (SSc). (PDF) Abstract, ACR National Meeting, 2006.
    
    
17. Schiopu E, Hsu VM, Impens AJ, Guerriere-Rothman JA, McCloskey DA, Wilson JE, Seibold JR:  Controlled trial of Tadalafil in Raynaud Phenomenon (RP) secondary to systemic sclerosis (SSc). (PDF) Abstract, ACR National Meeting, 2006.
    
    

Back to For Health Care Professionals - Top of Page